CN104203237A - 脒取代的β-内酰胺化合物、其制备和作为抗菌剂的用途 - Google Patents

脒取代的β-内酰胺化合物、其制备和作为抗菌剂的用途 Download PDF

Info

Publication number
CN104203237A
CN104203237A CN201380016121.9A CN201380016121A CN104203237A CN 104203237 A CN104203237 A CN 104203237A CN 201380016121 A CN201380016121 A CN 201380016121A CN 104203237 A CN104203237 A CN 104203237A
Authority
CN
China
Prior art keywords
amino
group
alkyl
oxygen base
azetidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380016121.9A
Other languages
English (en)
Chinese (zh)
Inventor
布克哈德·克伦克
伊瑞斯·维甘德
圭多·斯切夫
海克·布勒茨-厄斯特黑尔特
萨马尔恩德拉·N·迈蒂
杰汉吉尔·克汗
安德河·雷迪
志祥·杨
穆斯塔法·赫纳
国锋·贾
欧·立功
宏·梁
朱迪·叶
川军·高
萨比韩·塔贾姆
拉希姆·穆罕默德
甘谷丽·比斯瓦吉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris GmbH and Co KG filed Critical Aicuris GmbH and Co KG
Publication of CN104203237A publication Critical patent/CN104203237A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380016121.9A 2012-01-24 2013-01-23 脒取代的β-内酰胺化合物、其制备和作为抗菌剂的用途 Pending CN104203237A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
EP12152279.1 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (1)

Publication Number Publication Date
CN104203237A true CN104203237A (zh) 2014-12-10

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380016121.9A Pending CN104203237A (zh) 2012-01-24 2013-01-23 脒取代的β-内酰胺化合物、其制备和作为抗菌剂的用途

Country Status (42)

Country Link
US (2) US9556165B2 (enExample)
EP (1) EP2806873B1 (enExample)
JP (1) JP5869701B2 (enExample)
KR (1) KR102036393B1 (enExample)
CN (1) CN104203237A (enExample)
AP (1) AP2014007880A0 (enExample)
AR (1) AR089796A1 (enExample)
AU (1) AU2013211575B2 (enExample)
BR (1) BR112014017968A8 (enExample)
CA (1) CA2862338C (enExample)
CL (1) CL2014001956A1 (enExample)
CO (1) CO7101240A2 (enExample)
CU (1) CU24273B1 (enExample)
CY (1) CY1117955T1 (enExample)
DK (1) DK2806873T3 (enExample)
EA (1) EA027126B1 (enExample)
EC (1) ECSP14010249A (enExample)
ES (1) ES2592403T3 (enExample)
HR (1) HRP20161171T1 (enExample)
HU (1) HUE030452T2 (enExample)
IL (1) IL233805A (enExample)
IN (1) IN2014MN01640A (enExample)
LT (1) LT2806873T (enExample)
MA (1) MA35905B1 (enExample)
ME (1) ME02532B (enExample)
MX (1) MX346602B (enExample)
MY (1) MY173843A (enExample)
NZ (1) NZ626951A (enExample)
PE (1) PE20142345A1 (enExample)
PH (1) PH12014501671B1 (enExample)
PL (1) PL2806873T3 (enExample)
PT (1) PT2806873T (enExample)
RS (1) RS55210B1 (enExample)
SG (1) SG11201403930XA (enExample)
SI (1) SI2806873T1 (enExample)
SM (1) SMT201600354B (enExample)
TN (1) TN2014000297A1 (enExample)
TW (1) TWI659953B (enExample)
UA (1) UA110880C2 (enExample)
UY (1) UY34585A (enExample)
WO (1) WO2013110643A1 (enExample)
ZA (1) ZA201405057B (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175335A (zh) * 2015-08-13 2015-12-23 南阳师范学院 一种3-(3,3-二氯烯丙氧基)-1-甲基吡唑-5-甲酰胺衍生物及其制备方法
CN108368040A (zh) * 2015-12-15 2018-08-03 默沙东公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
CN108778273A (zh) * 2016-03-07 2018-11-09 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
WO2020098635A1 (zh) * 2018-11-13 2020-05-22 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
CN111253405A (zh) * 2020-03-20 2020-06-09 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN111303144A (zh) * 2019-12-13 2020-06-19 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN111448182A (zh) * 2017-10-02 2020-07-24 阿里萨制药有限公司 氨曲南衍生物及其用途
CN111592536A (zh) * 2020-06-04 2020-08-28 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物及其制备方法和应用
CN111675641A (zh) * 2020-06-04 2020-09-18 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111909067A (zh) * 2020-08-28 2020-11-10 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
CN118027019A (zh) * 2023-12-26 2024-05-14 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物的制备方法
CN118255695A (zh) * 2024-02-26 2024-06-28 广州艾奇西新药研究有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (en) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
HUE042134T2 (hu) * 2014-03-24 2019-06-28 Novartis Ag Monobaktám szerves vegyületek bakteriális fertõzések kezelésére
AU2016327264B2 (en) 2015-09-23 2019-06-27 Novartis Ag Salts and solid forms of monobactam antibiotic
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
WO2018038906A1 (en) 2016-08-26 2018-03-01 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
EP3541382A1 (en) * 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Liposomal formulations of amidine substituted beta-lactam compounds for use in the treatment of bacterial infections
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
CN110312715A (zh) 2016-12-21 2019-10-08 艾库里斯有限及两合公司 用于抗生素耐药性细菌菌株感染的使用脒取代的β-内酰胺化合物和β-内酰胺酶抑制剂的组合疗法
AU2018304841A1 (en) 2017-07-18 2020-02-06 Bayer Aktiengesellschaft Substituted 3-heteroaryloxy-1H-pyrazoles and salts thereof and their use as herbicidal active substances
WO2019020810A1 (en) 2017-07-28 2019-01-31 Aicuris Anti-Infective Cures Gmbh CRYSTALLINE FORM OF (2S) -2 - [[(Z) - [- 1- (2-AMINO-4-THIAZOLYL) -2 - [[(3S) -2,2-DIMETHYL-4-OXO] -Acid 1- (SULFOOXY) -3-AZETIDINYL] AMINO] -2-OXOETHYLIDENE] AMINO] OXY] -3- [4- [IMINO [(3R) -3-PIPERIDINYLAMINO] METHYL] PHENOXY] -PROPANOIC
ES2912656T3 (es) 2017-08-02 2022-05-26 Novartis Ag Proceso para preparar ácido 1-(((Z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoacetidin-3-il)amino)etiliden)amino)oxi)ciclopropano carboxílico
GEAP202215303A (en) * 2017-10-02 2022-04-11 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
EP3747883A4 (en) * 2018-01-29 2020-12-16 Medshine Discovery Inc. MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
WO2020125670A1 (zh) 2018-12-18 2020-06-25 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
US12516048B2 (en) 2020-08-06 2026-01-06 Ningxia Academy Of Agriculture And Forestry Sciences B-lactam compounds, their preparation and use as antibacterial agents
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
CR20240212A (es) 2021-11-18 2024-07-01 Merck Sharp & Dohme Llc Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas
WO2026043829A1 (en) * 2024-08-21 2026-02-26 Merck Sharp & Dohme Llc Chromane cyclic amidine monobactam compounds for the treatment of bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010324A1 (en) * 1997-08-29 1999-03-04 Naeja Pharmaceutical Inc. AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS
WO2002022613A1 (en) * 2000-09-14 2002-03-21 Pantherix Limited 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2008116813A2 (en) * 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd １−スルホ−２−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
JPH01290674A (ja) 1988-04-04 1989-11-22 E R Squibb & Sons Inc アゼチジニル誘導体
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
CA2554333A1 (en) 2004-01-27 2005-08-04 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
WO2008096189A2 (en) 2005-09-23 2008-08-14 M's Science Corporation Piperidine and piperazine derivatives
KR101403164B1 (ko) 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
KR101401139B1 (ko) 2006-02-14 2014-05-29 이하라케미칼 고교가부시키가이샤 5-알콕시-4-히드록시메틸피라졸 화합물의 제조방법
WO2007119511A1 (en) 2006-03-16 2007-10-25 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
CA2744756C (en) * 2008-12-19 2013-05-28 Pfizer Inc. Monocarbams and their use as antibacterial agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010324A1 (en) * 1997-08-29 1999-03-04 Naeja Pharmaceutical Inc. AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS
WO2002022613A1 (en) * 2000-09-14 2002-03-21 Pantherix Limited 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
WO2008116813A2 (en) * 2007-03-23 2008-10-02 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
CN105175335A (zh) * 2015-08-13 2015-12-23 南阳师范学院 一种3-(3,3-二氯烯丙氧基)-1-甲基吡唑-5-甲酰胺衍生物及其制备方法
CN108368040A (zh) * 2015-12-15 2018-08-03 默沙东公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
CN108368040B (zh) * 2015-12-15 2024-08-23 默沙东有限责任公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
US11230543B2 (en) 2015-12-15 2022-01-25 Merck Sharp & Dohme Corp. Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN108778273A (zh) * 2016-03-07 2018-11-09 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
CN108778273B (zh) * 2016-03-07 2022-06-17 默沙东公司 二环芳基单环β-内酰胺化合物及其用于治疗细菌感染的用途的方法
CN111448182A (zh) * 2017-10-02 2020-07-24 阿里萨制药有限公司 氨曲南衍生物及其用途
WO2020098635A1 (zh) * 2018-11-13 2020-05-22 南京圣和药业股份有限公司 单环内酰胺化合物及其应用
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN111303144A (zh) * 2019-12-13 2020-06-19 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN111253405A (zh) * 2020-03-20 2020-06-09 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物及其制备方法和应用
CN111675641A (zh) * 2020-06-04 2020-09-18 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536A (zh) * 2020-06-04 2020-08-28 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物及其制备方法和应用
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN115210231A (zh) * 2020-07-16 2022-10-18 宁夏农林科学院 新型单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
WO2022011626A1 (en) * 2020-07-16 2022-01-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
CN115210231B (zh) * 2020-07-16 2024-10-08 宁夏农林科学院 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067A (zh) * 2020-08-28 2020-11-10 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
WO2023082055A1 (zh) * 2021-11-09 2023-05-19 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途
CN118027019A (zh) * 2023-12-26 2024-05-14 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺化合物的制备方法
CN118255695A (zh) * 2024-02-26 2024-06-28 广州艾奇西新药研究有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Also Published As

Publication number Publication date
IL233805A (en) 2016-06-30
PH12014501671A1 (en) 2014-11-10
BR112014017968A8 (pt) 2017-07-11
AU2013211575A1 (en) 2014-07-24
ZA201405057B (en) 2017-09-27
WO2013110643A1 (en) 2013-08-01
PT2806873T (pt) 2016-09-23
KR102036393B1 (ko) 2019-10-24
SG11201403930XA (en) 2014-08-28
MA35905B1 (fr) 2014-12-01
US9556165B2 (en) 2017-01-31
SI2806873T1 (sl) 2016-10-28
NZ626951A (en) 2016-03-31
CO7101240A2 (es) 2014-10-31
PE20142345A1 (es) 2015-01-09
JP5869701B2 (ja) 2016-02-24
ES2592403T3 (es) 2016-11-30
PH12014501671B1 (en) 2020-02-28
AP2014007880A0 (en) 2014-08-31
UA110880C2 (uk) 2016-02-25
UY34585A (es) 2013-09-02
CA2862338C (en) 2019-04-16
AR089796A1 (es) 2014-09-17
EA201400838A1 (ru) 2014-12-30
ME02532B (me) 2017-02-20
CA2862338A1 (en) 2013-08-01
IN2014MN01640A (enExample) 2015-05-22
US20150045340A1 (en) 2015-02-12
DK2806873T3 (en) 2016-08-29
IL233805A0 (en) 2014-09-30
PL2806873T3 (pl) 2016-12-30
KR20140114390A (ko) 2014-09-26
LT2806873T (lt) 2016-10-10
SMT201600354B (it) 2016-11-10
MY173843A (en) 2020-02-24
RS55210B1 (sr) 2017-01-31
EP2806873B1 (en) 2016-06-15
HK1203389A1 (zh) 2015-10-30
US20170100379A1 (en) 2017-04-13
TW201343643A (zh) 2013-11-01
EA027126B1 (ru) 2017-06-30
TN2014000297A1 (en) 2015-12-21
TWI659953B (zh) 2019-05-21
CL2014001956A1 (es) 2014-11-07
AU2013211575B2 (en) 2017-03-02
US9782390B2 (en) 2017-10-10
JP2015504907A (ja) 2015-02-16
CY1117955T1 (el) 2017-05-17
HRP20161171T1 (hr) 2016-11-04
BR112014017968A2 (enExample) 2017-06-20
MX346602B (es) 2017-03-24
CU20140090A7 (es) 2014-12-26
CU24273B1 (es) 2017-08-08
MX2014008915A (es) 2014-08-26
ECSP14010249A (es) 2015-12-31
EP2806873A1 (en) 2014-12-03
HUE030452T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
TWI659953B (zh) 經脒取代之β－內醯胺化合物，其製備及用途
RU2746129C2 (ru) Биарильные монобактамные соединения и способы их применения для лечения бактериальных инфекций
ES2550312T3 (es) Antagonistas ciclohexil-azetidinilo de CCR2
EP3426248A1 (en) Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
US12516048B2 (en) B-lactam compounds, their preparation and use as antibacterial agents
JP4437078B2 (ja) 抗菌性アミドマクロサイクル
CN110049970B (zh) 作为细菌氨酰-trna合成酶抑制剂的2-氨基-n-(芳基亚磺酰基)-乙酰胺化合物
CN113614095B (zh) 作为精氨酸酶抑制剂的烷基硼酸类化合物
TWI829686B (zh) 氧基取代化合物
JP2008502583A (ja) 抗細菌性アミド大員環
CN108602822A (zh) 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途
CN115210231B (zh) 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
CN114828850B (zh) 化合物在制药中的应用
HK1203389B (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
OA17341A (en) Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents.
WO1993006102A1 (fr) Derive de 2-(pyrrolidinylthio substitue) carbapenem
WO1985001287A1 (fr) Derives de 2-azetidinone et leur procede de preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141210